Cartalax

Cartalax is a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp-Gly and a molecular weight of approximately 390.35 Da, developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the same peptide bioregulator research program that produced Epitalon and Pinealon — with research focus on its role as a tissue-specific bioregulator for cartilage, connective tissue, and musculoskeletal biology.

Developed within the framework of peptide bioregulator theory — which proposes that short peptides derived from specific tissues act as tissue-specific gene expression regulators — Cartalax has been studied for its effects on chondrocyte proliferation and differentiation, extracellular matrix synthesis in cartilage tissue, and the regulation of collagen and proteoglycan production in connective tissue models, with research examining its potential role in age-related cartilage degradation and musculoskeletal tissue maintenance in preclinical models.

Research has focused on Cartalax’s role as a connective tissue-specific peptide bioregulator — with its tissue-targeted mechanism complementing the broader longevity and regenerative research applications of related bioregulators such as Epitalon (telomere regulation), Thymalin (immune bioregulation), and BPC-157 (multi-tissue cytoprotection) for comprehensive tissue biology research. For further reading see: Peptide bioregulator research and tissue-specific regulation (PubMed).

Specifications:

• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: −20°C

For Research Use Only.